News | April 29, 2023
Evonik starts construction of new U.S. facility for pharmaceutical lipids
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
The business and product range of Ipca and that of Unichem complements each others business and product range
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Apollo continues to invest in genomics technology and research for better patient care
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Subscribe To Our Newsletter & Stay Updated
